ctDNA detection linked to 10-fold and 50-fold higher recurrence risk

A plain-language summary of the α-CORRECT study reports that detectable circulating tumour DNA after surgery or during surveillance was associated with a much higher likelihood of recurrence in stage III colorectal cancer. The result supports ctDNA as a prognostic marker, but does not show that changing treatment based on the test improves survival.

The study at a glance

Study design	Plain-language summary of the α-CORRECT study; the underlying study design is not reported in the supplied abstract.
Who took part	Patients with stage III colorectal cancer after treatment; the supplied abstract does not report the number of participants.
What was tested	A blood test for circulating tumour DNA, used to detect molecular residual disease after surgery and during surveillance.
What was measured	Whether ctDNA detection predicted later colorectal cancer recurrence, and how long before recurrence it was detected compared with symptoms or imaging.

What this publication reports

This publication is a plain-language summary of the α-CORRECT study, rather than the original research report. That distinction affects what we can assess. The supplied abstract describes the study’s broad findings, but does not provide the participant number, length of follow-up, test-performance measures, confidence intervals, or details of the statistical analysis.

The underlying work concerned people with stage III colorectal cancer, meaning cancer had spread to nearby lymph nodes but had not been identified at distant sites. These patients commonly have surgery followed by chemotherapy. Even after this treatment, some people later develop recurrence, when the cancer returns.

α-CORRECT evaluated a blood-based test for circulating tumour DNA, or ctDNA. This is fragmented genetic material released into the bloodstream by cancer cells. The test was intended to identify molecular residual disease, often shortened to MRD: evidence at a molecular level that cancer may remain despite no visible tumour on a scan and no symptoms.

The central question was prognostic. Could a positive ctDNA result identify people more likely to have their cancer recur? Prognostic tests estimate the likely course of a disease. They do not, by themselves, establish which treatment will improve that course.

A positive result was associated with substantially higher recurrence risk

According to the summary, people with MRD detected after surgery had a recurrence likelihood about 10 times higher than people with no MRD detected. During the surveillance period, the reported recurrence likelihood was about 50 times higher among people with detectable MRD than among those without detectable MRD.

Surveillance is the period of scheduled follow-up after initial treatment, typically involving clinical review, imaging and blood testing. The larger association during surveillance may reflect that a ctDNA-positive result at that later point identifies disease that has persisted or become detectable in the bloodstream. The supplied summary does not provide the underlying recurrence rates, so it cannot tell us the absolute chance of recurrence for either group.

These are associations from a study of a test and subsequent outcomes. They show that ctDNA detection and later recurrence occurred together far more often than ctDNA non-detection and recurrence. They do not show that ctDNA causes recurrence, nor that any particular response to a ctDNA result will prevent it.

The size of the reported associations makes the finding clinically compelling as a signal of risk. But risk estimates also need context: how often did the test miss recurrences, how often was ctDNA detected without a later observed recurrence, and how precise were the estimates? The abstract supplied for this article does not answer those questions.

The test reportedly gave an earlier warning than usual follow-up

The summary reports that, during follow-up, the MRD test detected ctDNA about 10 months before recurrence was found through symptoms or imaging. Imaging may include computed tomography, or CT, and positron emission tomography, or PET. Both look for visible signs of cancer, whereas ctDNA testing seeks a blood signal that may appear before a tumour is large enough to see.

Earlier detection can be useful only if it leads to an action that improves an outcome patients care about, such as survival, quality of life, or the ability to receive curative treatment. α-CORRECT, as described here, assessed prediction and timing of detection. It was not designed to show that treatment prompted by ctDNA improves survival.

That gap is the important one. A test may identify recurrence risk months before standard methods do, yet clinicians still need evidence about the best next step after a positive result. More chemotherapy, a different drug, earlier imaging, or closer observation could have different benefits and harms. Some people with a negative result may also still recur, because no test detects every case.

The summary says ongoing clinical studies are examining how MRD results might guide treatment decisions. Those trials, particularly trials that assign treatment according to ctDNA results and measure patient outcomes, are needed before a prognostic blood test can establish a treatment-changing role.

Where this leaves patients and clinical teams

For someone treated for stage III disease, ctDNA is understandable as an appealing idea. A blood test that might identify a high-risk situation before a scan changes could potentially make follow-up more informative. The α-CORRECT summary adds to the evidence that detectable ctDNA can mark a group with a much higher risk of recurrence.

It does not establish a standard treatment pathway after a positive test or prove that a negative test means recurrence cannot occur. Nor does it provide enough detail in this publication to judge how the result varies by tumour features, treatment received, timing of blood collection, or assay method. Different ctDNA tests can use different laboratory approaches, which may matter for performance and interpretation.

As both a scientist and a patient, I think the useful way to read this is as evidence of a strong prognostic signal, alongside a still-unresolved treatment question. A positive ctDNA result may identify a reason for a more focused conversation with an oncology team. It cannot yet answer, on its own, whether additional treatment will help a particular person live longer or live better.

The next evidence that would change the discussion is evidence from outcome-focused trials: does a ctDNA-guided strategy improve survival or other patient-centred outcomes compared with standard follow-up, and what harms accompany that strategy?